Sleep disordered breathing, includin g obstructive sleep apnea, is a commo n and morbid health problem. Traditionally, sleep disordered breathin g is diagnosed by complex sleep studies. However, newer, easy-to-use, highly sensitive, and highly specific hom e sleep study equipment is now availabl e. The present study was undertaken to determine whether an otolaryngo logist could easily and effec tively dispense home sleep equipment fro m the office. We used a portable AutoSet home sleep machine. Our expe rience with thefi rst 100 consecutively presenting patients was recorde d and analyzed under institutional review board app roval.
Introduction
Sleep disordered breathing (SDB) is a serious publi c health probl em , affec ting 40 million adul t Ameri ca ns.1·3 Most of the se pat ient s suffer from a part icul ar form of SDB known as obstructive sleep apnea (GSA). GSA is character ized by epi sodic cessatio ns of breathin g during sleep because of the collapse or blo cka ge of the uppe r airway, which causes oxygen desatu ration s, fluctu ation s in heart rate and blood pressure, frequent arousa ls fro m sleep, decreases in growth and immune modul ators, and excessive daytime slee piness .
Using the most liber al definition of GS A-an apneahypopnea index (AHI) of 5 eve nts per hour-one landmark study found that up to 24% of men and 9% of women had GSA. 4 Using a stricter diagno stic criteri a-an AHI of at least 15 events per hour plu s a histor y of daytime hypersom nolence-the same study repo rted that 4% of men and 2% of wom en suffe red from GSA.
Makin g the dia gnosis is imperative because when GSA is left untre ated , it is ass ociated with sig nific ant mort ality and morbid ity brou ght on by hyp ert en sion , obesity, transient ischemi c att acks, stroke, conges tive he art failure, and myoc ardi al infarction.' Because the dia gnosis cannot be made by clinical history or phy sical ex amination alon e.s-' detection has traditionally invo lved the measurement of the AHI by pol ysomn ography (PSG). PSG entail s monit orin g at least seven parameters during an overnig ht sleep study in a laboratory , with a technician present throu ghout the entire study. Th e seven main par ameters are electroe nce pha log raphy (EEG), electro-oculograph y (EGG) , chin elec tro myography (EMG), electroc ardiogra phy (ECG) , airflow, respir atory effo rt, and oxygen saturation.
Alth ough PSG res ults remain the gold sta ndard for the diagno sis of GSA , its high cos t and limited avail ability make the portabl e, unattended sleep monitoring sys tem an increasin gly attrac tive alterna tive . Portable monit ors have been valida ted in numerous studies .":" They measure different paramete rs depending on the model. Hom e . monitors hold so me adva ntages over PSG: they allow for wider acces s to slee p studies, they do so at a lower cost, and they allow patients to sleep in their normal environment , thu s min imi zin g the "first-night effect" often associated with PSG. 1 5 Moreover, because the data from these portabl e devices are relatively easy to inter pret and have a high degree of sensitivity and spec ificity," more ph ysici ans have the ca pability to eva luate patient s who present with a history
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Decreased fertilityin male rats, shown bylower female conceptionrates, occurred atan oral dose of 64 mg/kg (appro ximately 50 times the maximum recommended human dail y oral dose on a mg/m 2 basis) and was reversible with ces sation of dosing . Loratadine had no effect on male or female fertility or reprod uction in therat at an oral dose of approximately 24 mg/kg (approximatel y 20times themaximum recommended human dailyoral doseona mg/m 2 basis) .
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Pediatric Use: The safetyof CLAR ITINSyrupata daily dose of 10 mg has been demonstrated in 188 pediatric patients 6-12 years of age in placebo-controlled 2-week trials. The effectiveness of CLAR ITIN for the treatment Qf seasonal allergic rhi nitis andchronic idiopathic urticaria in this pediatric age group is based on an ext rapolation of the demonstrated efficacy of CLARITIN in adults in thesecondinons and thelikeli hQod thatthedisease course, pathophysiology, and the drug's effect are substantially similar to that of theadults. The recommended dose for theped iatric population is based oncross-study comparison of the pharmacokinetics of CLARITINin adultsand pediatric subjectsand onthesafety profil e ot loratadine in bot h ad ults and ped iatric patients atdoses equal to or higherthan therecommended doses. Thesafety and effectiveness of CLAR ITIN in pediatric pat ients under 6 yearsof age have not been established . 
lin a car driving suggestive of GSA. This is especially important for of their snoring and had lost an important symptom of otolaryngologists, who can use these devices not only to SDB, which went undetected because the snoring had evaluate snoring and GSA, but to monitor postsurgical been eliminated. The result was that these patients re-AHIs as well . This latter fact might hold significant mained at significant risk for morbidity and mortality. prognostic implications. For example, He et al found that As otolaryngologists continue to exhibit more interest the incidence of mortality from SDB following in sleep medicine and surgeryt-i-including procedures uvulopalatopharyngoplasty remained high. 5 He expressed such as phase IIII surgery ,17 laser-assisted uvuloplasty,18-20 concern that some of these patients might have been cured and most recently radio -frequency surgery 'l-e-and as cost-effective sleep tests become available in many parts of the country and the world, there is a great need for sleep testing capabilities in the ENT office.
Materials and methods
We studied l Ot) con secutively presenting adults , 83 men and 17 women (mean age: 52), who were suspec ted of having sleep apnea syndrome and who were referred to 
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AHI of 15 or higher, 84% had an AHI of 10 or higher, and 93 % had an AHI of at least 5. Among the 100 tests, 99 were completed successfullyon the first attempt. The failure had to be repeated because of a patient error in performing the study; this patient completed the test successfully on the second attempt.
Discussion
Otolaryngologists monitors, records, and adjusts pressure in response to snoring, apneas , and hypopneas. Medical and surgical treatment paradigms are then discussed with the patient and the referring physicians. We devised a clinical algorithm to summarize our general approach (figure 5) .
Results
The results of the home sleep studi es on our 100 patients are shown in the RlI10FlLm i different than anylhll1g your paucnts h.ivc tried before. It provides ;1 gC11l1c aerosol mu that soothes and dean C ' naturally, \\ ithout drugs. And It offer two thcrap, sciungs: Phase One washes, hydrate .md drams the na al cavi ty : Phase '1\\ 0 promote drainage of the SII1t1"C~providiru; an added InTI of rchcl. Rmollow will complement your medical management 01 chronic SIl1USIIIS Table. Mean values for 100 patients tested for obstructive sleep apnea with a multichann el home sleep machine Figure 6 . Facto rs that influence the choice between surgery and continuous positive airway pressure (CPAP) treatment for patients w ith obstructive sleep apnea.
Pretest symptom scores (see figure 1)
Snor ing 2.5 (± 0.9) W itnessed apneic episodes 2.3 (± 1.6) Daytime hypersomnolence 3.0 (± 1.3) Morning headache 1.2 (± 1.4) Arm/l eg movements 2.0 (± 1.6) Epworth sleepiness sco re 12.0 (±6.0; normal.<t t) encouraged to master CPAP or consi der tracheostomy. In summary, we believe our study answers the question of whethe r or not otolary ngo logis ts ca n confidently prescribe and administer multi channel home sleep studies. With a sta te-of-the-art mach ine, these studies were easi ly performed and the results were easily recorded and interpreted. Our results were simila r to those reported in laboratory slee p studies by sleep-traine d physicians. We conclude that with the use of the AutoSet portable monitor, an oto laryngologi st can cos t-effectively prescribe multichanne l ho me sleep studies, there by greatly enha ncing the ENT evaluation and treatment of sleep disordered breathing. 
